Last reviewed · How we verify
fluticasone 25, 50, 100, 200 mcg
fluticasone 25, 50, 100, 200 mcg is a Small molecule drug developed by St. Joseph's Healthcare Hamilton. It is currently FDA-approved.
At a glance
| Generic name | fluticasone 25, 50, 100, 200 mcg |
|---|---|
| Sponsor | St. Joseph's Healthcare Hamilton |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects (PHASE2)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
- Relovair PD PK in Chinese Healthy Subjects (PHASE1)
- Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler (PHASE1)
- A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fluticasone 25, 50, 100, 200 mcg CI brief — competitive landscape report
- fluticasone 25, 50, 100, 200 mcg updates RSS · CI watch RSS
- St. Joseph's Healthcare Hamilton portfolio CI
Frequently asked questions about fluticasone 25, 50, 100, 200 mcg
What is fluticasone 25, 50, 100, 200 mcg?
fluticasone 25, 50, 100, 200 mcg is a Small molecule drug developed by St. Joseph's Healthcare Hamilton.
Who makes fluticasone 25, 50, 100, 200 mcg?
fluticasone 25, 50, 100, 200 mcg is developed and marketed by St. Joseph's Healthcare Hamilton (see full St. Joseph's Healthcare Hamilton pipeline at /company/st-joseph-s-healthcare-hamilton).
What development phase is fluticasone 25, 50, 100, 200 mcg in?
fluticasone 25, 50, 100, 200 mcg is FDA-approved (marketed).